Idorsia Pharmaceuticals Ltd
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Idorsia Pharmaceuticals Ltd
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
The first-in-class, oral GPR35 agonist has shown preclinical promise as a potential treatment for gastrointestinal indications such as ulcerative colitis.
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
In Alnylam’s Search For A Mass-Market Treatment, A Twice Yearly Blood Pressure Injection Could Fit The Bill
Alnylam is using its RNA interference technology to target hypertension, which could create a true mass-market cardiovascular blockbuster drug for the firm – but upcoming Phase II data will need to be compelling.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Vaxxlion AG
- Vaxxlion Ltd
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.